144 related articles for article (PubMed ID: 2803926)
21. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction.
Bièche I; Franc B; Vidaud D; Vidaud M; Lidereau R
Thyroid; 2001 Feb; 11(2):147-52. PubMed ID: 11288983
[TBL] [Abstract][Full Text] [Related]
22. Amplification, rearrangements, and enhanced expression of c-myc in chemically induced rat liver tumors in vivo and in vitro.
Suchy BK; Sarafoff M; Kerler R; Rabes HM
Cancer Res; 1989 Dec; 49(23):6781-7. PubMed ID: 2684400
[TBL] [Abstract][Full Text] [Related]
23. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
[TBL] [Abstract][Full Text] [Related]
24. Oncogene expression in follicular neoplasms of the thyroid.
Auguste LJ; Masood S; Westerband A; Belluco C; Valderamma E; Attie J
Am J Surg; 1992 Dec; 164(6):592-3. PubMed ID: 1361106
[TBL] [Abstract][Full Text] [Related]
25. [The role of genetic factors in the pathogenesis of thyroid neoplasms].
Ferenc T; Maciaszczyk K; Gesing A; Lewiński A
Postepy Hig Med Dosw; 1997; 51(4):367-84. PubMed ID: 9446100
[TBL] [Abstract][Full Text] [Related]
26. Oncogenes and growth factors in thyroid carcinogenesis.
Frauman AG; Moses AC
Endocrinol Metab Clin North Am; 1990 Sep; 19(3):479-93. PubMed ID: 2175702
[TBL] [Abstract][Full Text] [Related]
27. c-myc oncogene alterations in human thyroid carcinomas.
del Senno L; Gambari R; degli Uberti E; Barbieri R; Bernardi F; Buzzoni D; Marchetti G; Pansini G; Perrotta C; Conconi F
Cancer Detect Prev; 1987; 10(3-4):159-66. PubMed ID: 2436779
[TBL] [Abstract][Full Text] [Related]
28. [Joint amplification of c-myc and c-Ha-ras oncogenes in human breast and thyroid cancer cells].
Pluzhnikova GF; Serova OM; Kniazev PG; Fedorov SN; Novikov LB
Eksp Onkol; 1987; 9(2):15-7. PubMed ID: 3034547
[TBL] [Abstract][Full Text] [Related]
29. Expression of cellular oncogenes in primary cells from human acute leukemias.
Mavilio F; Sposi NM; Petrini M; Bottero L; Marinucci M; De Rossi G; Amadori S; Mandelli F; Peschle C
Proc Natl Acad Sci U S A; 1986 Jun; 83(12):4394-8. PubMed ID: 3520570
[TBL] [Abstract][Full Text] [Related]
30. Detection of activated ras oncogenes in human thyroid carcinomas.
Suárez HG; Du Villard JA; Caillou B; Schlumberger M; Tubiana M; Parmentier C; Monier R
Oncogene; 1988 Apr; 2(4):403-6. PubMed ID: 3283656
[TBL] [Abstract][Full Text] [Related]
31. Expression of c-fos and c-myc proto-oncogenes in human adrenal pheochromocytomas.
Goto K; Ogo A; Yanase T; Haji M; Ohashi M; Nawata H
J Clin Endocrinol Metab; 1990 Feb; 70(2):353-7. PubMed ID: 2405002
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of c-myc gene and c-fos gene in premalignant and malignant tissues from patients with familial polyposis coli.
Sugio K; Kurata S; Sasaki M; Soejima J; Sasazuki T
Cancer Res; 1988 Sep; 48(17):4855-61. PubMed ID: 2842040
[TBL] [Abstract][Full Text] [Related]
33. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
[TBL] [Abstract][Full Text] [Related]
34. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
Tavassoli M; Quirke P; Farzaneh F; Lock NJ; Mayne LV; Kirkham N
Br J Cancer; 1989 Oct; 60(4):505-10. PubMed ID: 2572268
[TBL] [Abstract][Full Text] [Related]
35. High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix.
Ocadiz R; Sauceda R; Cruz M; Graef AM; Gariglio P
Cancer Res; 1987 Aug; 47(15):4173-7. PubMed ID: 3300961
[TBL] [Abstract][Full Text] [Related]
36. Role of ras and gsp oncogenes in human epithelial thyroid tumorigenesis.
Du Villard JA; Schlumberger M; Wicker R; Caillou B; Rochefort P; Feunteun J; Monier R; Parmentier C; Suarez HG
J Endocrinol Invest; 1995 Feb; 18(2):124-6. PubMed ID: 7629378
[No Abstract] [Full Text] [Related]
37. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
38. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
40. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
